influenza pneumonia
Conditions
Interventions
Group 1:basic treatment+Oseltamivir+recombinant human interferon a1b
Group 2:Basic treatment+oseltamivir + inhalation mimetic
Sponsors
Beijing Ditan Hospital Capital Medical University
Eligibility
Sex/Gender
Male
Age
14 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients of community-acquired pneumoniaage ,14-70. Gender does not limit; 2. Meet the clinical-defined virus pneumonia criteria: 1) fever(oral temperature=38.0 degree C, or axillary temperature =37.4 degree C, or prior history of fever within 48h; 2) with or without dyspenia; 3) Chest radiogram manifestation: unilateral or bilateral chest radiogram test showed multiple (at least two lesions) or diffuse distribution of patchy or glass attenuation infiltrates (with or without consolidation); 3. Etiological examination confirm virus infection exclude influenza virus; 4. Onset time=5d; 5. Patients are able to accept nebulized inhalation treatment; 6. Willing and to be able to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Clear laboratory evidence of Streptococcus ,Legionella pneumophila, Mycoplasma, Chlamydia infection, Adenovirus, respiratory syncytial virus, rhinovirus, etc.; 2. Clear laboratory and clinical evidence of bacterial infection. e.g. PCT>1ug/L; 3. Use antiviral drugs within 1 week, and will use anther antiviral drug during the course of the disease; 4. Current or prior hisrtory of critical lung basic diseases: pulmonary tuberculosis, lung cancer, pulmonary edema, atelectasis, pulmonary embolism, pulmonary eosinophilic infiltration and pulmonary vasculitis; 5. Severe hepatic and renal function with significant abnormalities: (1) AST, ALT is over 10 times more than the upper limits of normal; (2) serum creatinine is over 1.5 times more than the upper limits of normal; 6. Particpating another clinical studies within 30 days; 7. Allergic history of interferonor contraindication to interferon: angina, myocardial infarction and other serious cardiovascular disease; history of epilepsy or other central nervous system diseases; obvious abnormal hematopoietic system (platelet <30*10^9/L, the neutral granular cell <0.5*10^9/L); 8. Pregnant or nursing; 9. The survival time maybe less than 48 hours from screening; 10. Those subjects are not suitable for this study by investigator's judgement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alleviate symptoms of pneumonia; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization time;Incidence of secondary bacterial pneumonia and antibiotic application;Viral quantity of throat swab; | — |
Countries
China
Contacts
Public ContactJiang Rongmeng
The Center of Infectious Diseases of Beijing Ditan Hospital Capital Medical University
Outcome results
None listed